Myeloma Minute: Good News, Bad News in Current Science Climate


| INNOVATION | Latest Research


Silver Linings Soften Spate of Science Program Budget Cuts

Recent budget cuts have hit programs that monitor toxic exposure, investigate climate change, and speed scientific discoveries. Fortunately, IMF Chairman Dr. Brian G.M. Durie finds lots of exciting new research, including a way to bring a long-extinct bird back to life.


| INNOVATION | Clinical Trials


| EDUCATION | Awareness


Phase III Isatuximab Clinical Trials
Racial Disparities in Myeloma Care

Two new phase III clinical trials of isatuximab, an anti-CD38 monoclonal antibody, are enrolling myeloma patients. The IKEMA study assesses the clinical benefit of isatuximab combined with Kyprolis® and dexamethasone in patients with relapsed and/or refractory disease previously treated with one to three prior lines of therapy. The IMROZ study assesses the clinical benefit of isatuximab in combination with Velcade®, Revlimid®, and dexamethasone in patients with newly diagnosed myeloma not eligible for transplant.

Cancer Therapy Advisor interviews the author of the first comprehensive study of racial disparities in the diagnosis and treatment of myeloma. “The picture is complex and, clearly, much needs to be done to improve access to ideal care,” says IMF Chairman Brian G.M. Durie.



| ACTION | Advocacy


IMF Advocacy Team Relaunches Coalition

On Tuesday, March 6, 2018, the Patients Equal Access Coalition (PEAC), which is run by the IMF advocacy department, held an event in Washington, D.C. to relaunch the coalition as the Coalition to Improve Access to Cancer Care (CIACC). The relaunch effort will enhance our ability to pass legislation that would prevent insurance companies from applying different co-pays to oral cancer medicine than they do to chemotherapy or other injected treatments through H.R. 1409, the Cancer Drug Parity Act of 2017. The CIACC launched with a new name, logo and website as well as a major awareness campaign on Capitol Hill held on March 7th. Learn more about legislation, relaunch, and the Hill day.


| EMPOWERMENT | Myeloma Action Month


Add a Myeloma Warrior Frame to Your Facebook Profile Photo

This year’s Myeloma Action Month campaign focuses on individuals like YOU who are surviving with the disease, supporting loved ones, or helping to find the cure. Remember to add an official Myeloma Warrior frame to your Facebook (FB) profile photo. Here’s how:

1) STEP 1: LIKE the International Myeloma Foundation Facebook page at

2) STEP 2:

  • a. Visit your personal Facebook (FB) page.
  • b. Mouse-over your FB profile photo.
  • c. Select Update Profile Picture
  • d. Enter IMF Myeloma in the search box.
  • e. Click Add Frame
  • f. Select the Myeloma Warrior frame of your choice.



| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series



BOSTON Trial Fact Sheet

New isatuximab Clinical Trial: the IMROZ Study

New isatuximab Clinical Trial: the IKEMA Study

New ixazomib Clinical Trials: Learn How to Participate

Join the conversation about myeloma on the Smart Patients Message Board

March 10, 2018
IMF Regional Community Workshop

Denver, CO

March 10, 2018
2nd Annual Masters Tennis for Myeloma
The Villages, FL

March 16-17, 2018
IMF Patient & Family Seminar
Boca Raton, FL

April 8, 2018
Julianne’s Rock n’ Roll Half-Marathon
San Francisco, CA

April 21, 2018
IMF Regional Community Workshop
Nashville, TN

April 28, 2018
Miles for Myeloma 5K Walk/Run
Philadelphia, PA

May 5-6, 2018
Miracles Happen When Pigs Fly!
Cincinnati, OH


subscribe_button.png          donate_button_bottom.png
We Thank Our Sponsors:
Amgen, Celgene Corporation, Genentech, Janssen Oncology, and Takeda Oncology
and individuals like you who supported the IMF this year

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.